Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40 minutes
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 5 AUG 24 CA/CAplus enhanced with legal status information for U.S. patents
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS 10 NOV 23 Addition of SCAN format to selected STN databases
NEWS 11 NOV 23 Annual Reload of IFI Databases
NEWS 12 DEC 01 FRFULL Content and Search Enhancements
NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and sequence information
NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus

NEWS 18 JAN 12 Match STN Content and Features to Your Information Needs, Quickly and Conveniently
NEWS 19 JAN 25 Annual Reload of MEDLINE database
NEWS 20 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download
NEWS 21 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts
NEWS 22 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 23 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content and Features
NEWS 24 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail Addresses

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2, AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:48:24 ON 19 FEB 2010

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.22	0.22

FILE 'CAPLUS' ENTERED AT 11:48:42 ON 19 FEB 2010

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2010 VOL 152 ISS 9
FILE LAST UPDATED: 18 Feb 2010 (20100218/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s T25 and HDAC
324 T25
3692 HDAC
1335 HDACS
4104 HDAC
(HDAC OR HDACS)
L1 2 T25 AND HDAC

=> duplicate remove L1
PROCESSING COMPLETED FOR L1
L2 2 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)

=> d L2 bib abs 1-2

L2 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2008:748783 CAPLUS
DN 149:143418
TI Monitoring the effect of belinostat in solid tumors by H4 acetylation
AU Marquard, Lena; Petersen, Kamille Dumong; Persson, Morten; Hoff, Kirsten Damgaard; Jensen, Peter Buhl; Sehested, Maxwell
CS Experimental Pathology Unit, Copenhagen University Hospital, Copenhagen, Den.
SO APMIS (2008), 116(5), 382-392

CODEN: APMSEL; ISSN: 0903-4641
PB Blackwell Publishing Ltd.
DT Journal
LA English
AB Histone deacetylase (HDAC) inhibition is a novel entity in medical oncol., and several HDAC inhibitors are in clin. trials. One of them is the hydroxamic acid belinostat (PXD101) that has demonstrated therapeutic efficacy for several clin. indications. Acetylation of histones is a key event after treatment with HDAC inhibitors, and could thus be used as a marker for monitoring cellular response to HDAC inhibitor treatment. Here we describe the utility of a newly described monoclonal antibody against acetylated H4 for immunohistochem. on paraffin-embedded fine needle biopsies from nude mice carrying A2780 human ovarian cancer xenografts. Acetylated H4 was monitored in vivo by immunohistochem. during treatment with belinostat, and compared with pharmaco-kinetics in plasma and tumor tissue. We found an increased level of acetylated H4 15 min after a single treatment (200 mg/kg i.v.) with max. level reached after 1 h. H4 acetylation intensity reflected the belinostat concn. in plasma and tumor tissue. The threshold level for belinostat activity, indicated by acetylated H4, correlated with belinostat plasma concns. above 1,000 ng/mL. In conclusion, examn. of H4 acetylation in fine needle biopsies using the T25 antibody may prove useful in monitoring HDAC inhibitor efficacy in clin. trials involving humans with solid tumors.
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:266919 CAPLUS
DN 140:281367
TI Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
IN Pelicci, Pier Giuseppe; Minucci, Saverio; Piccini, Daniele; Maccarana, Marco; Ronzoni, Simona; Areces, Liliana Beatriz; Faretta, Marco
PA G2m Cancer Drugs Ag, Germany
SO Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1403639	A1	20040331	EP 2002-21984	20020930

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
CA 2500384 A1 20040408 CA 2003-2500384 20030930
WO 2004029622 A2 20040408 WO 2003-EP10842 20030930
WO 2004029622 A3 20040805
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003271663 A1 20040419 AU 2003-271663 20030930
EP 1546712 A2 20050629 EP 2003-753482 20030930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006501279 T 20060112 JP 2004-539052 20030930
US 20060257948 A1 20061116 US 2005-529792 20051110
PRAI EP 2002-21984 A 20020930
WO 2003-EP10842 W 20030930
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention relates to a method for detg. whether a treatment of a disorder with an histone deacetylases (HDAC) inhibitor is to be started/continued or not comprising detg. the level of histone acetylation in the sample by use of an antibody capable of binding to acetylated histone, and classifying the disorder as to be treated with an HDAC inhibitor when the level of histone acetylation is significantly lower than that of a ref. sample. The invention further relates to the diagnostic and prognostic use of specific antibodies and cell lines producing them.
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s T52 and HDAC
40 T52
3692 HDAC
1335 HDACS
4104 HDAC

(HDAC OR HDACS)
L3 2 T52 AND HDAC

=> duplicate remove L3
PROCESSING COMPLETED FOR L3
L4 2 DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)

=> d L4 bib abs 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:642598 CAPLUS
DN 144:208314
TI New method to detect histone acetylation levels by flow cytometry
AU Ronzoni, Simona; Faretta, Mario; Ballarini, Marco; Pelicci, PierGiuseppe; Minucci, Saverio
CS European Institute of Oncology, Milan, Italy
SO Cytometry, Part A (2005), 66A(1), 52-61
CODEN: CPAYAV; ISSN: 1552-4922
PB Wiley-Liss, Inc.
DT Journal
LA English
AB Background: Reversible histone acetylation affects chromatin structural organization, thus regulating gene expression and other nuclear events. Levels of histone acetylation are tightly modulated in normal cells, and alterations of their regulating mechanisms have been shown to be involved in tumorigenesis. Methods: the authors developed a new flow cytometric technique for detection of histone acetylation, based on a specific monoclonal antibody that recognizes acetylated histone tails. Bivariate anal. for histone acetylation levels and DNA were performed to study modulation of chromatin organization during the cell cycle and after induction of histone hyperacetylation by the histone deacetylase (HDAC) inhibitor trichostatin A (TSA). Histone acetylation and transcription levels were monitored during differentiation induced by retinoic acid alone or in combination with TSA. Blood samples from patients were analyzed with the described protocol to monitor the effects of HDAC inhibitors in vivo and validate the developed protocol for clin. usage. Results: Flow cytometric detection of acetylation status can successfully detect modifications induced by HDAC inhibitor treatment in vivo as demonstrated by anal. of various blood samples from patients treated with valproic acid. Changes in acetylation levels during the cell cycle demonstrated a reproducible increase in histone acetylation during the replication phase that was subsequently decreased at the G2M entrance, thus paralleling the behavior of DNA replication and transcriptional activity. Conclusions: Multiparameter anal. of histone acetylation and expression of mol. markers, DNA ploidy, and/or cell cycle kinetics can provide a quick and statistically reliable tool for the

diagnosis and evaluation of treatment efficacy in clin. trials using HDAC inhibitors.
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2004:266919 CAPLUS
DN 140:281367
TI Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
IN Pelicci, Pier Giuseppe; Minucci, Saverio; Piccini, Daniele; Maccarana, Marco; Ronzoni, Simona; Areces, Liliana Beatriz; Faretta, Marco
PA G2m Cancer Drugs Ag, Germany
SO Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1403639	A1	20040331	EP 2002-21984	20020930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2500384	A1	20040408	CA 2003-2500384	20030930
WO 2004029622	A2	20040408	WO 2003-EP10842	20030930
WO 2004029622	A3	20040805		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003271663	A1	20040419	AU 2003-271663	20030930
EP 1546712	A2	20050629	EP 2003-753482	20030930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501279	T	20060112	JP 2004-539052	20030930
US 20060257948	A1	20061116	US 2005-529792	20051110
PRAI EP 2002-21984	A	20020930		

WO 2003-EP10842 W 20030930
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The invention relates to a method for detg. whether a treatment of a disorder with an histone deacetylases (HDAC) inhibitor is to be started/continued or not comprising detg. the level of histone acetylation in the sample by use of an antibody capable of binding to acetylated histone, and classifying the disorder as to be treated with an HDAC inhibitor when the level of histone acetylation is significantly lower than that of a ref. sample. The invention further relates to the diagnostic and prognostic use of specific antibodies and cell lines producing them.
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT